Metabolic & Cardiometabolic
GLP-1 limits postprandial glucose
In plain terms: Does the gut hormone GLP-1 keep blood sugar down after a meal?
Strong support Metabolic & Cardiometabolic 💰 Industry COI noted
Part of: 💊 GLP-1 Drugs
RefutedContestedStrong support
consensus score 1.00
Yes — this is well-established core physiology, the same biology behind GLP-1 weight-loss drugs.
🧭 Read this score with how it was built in mindA study was counted as evidence for something it never varied
Read the score here with its shape in mind. Every study still voting on this claim gave GLP-1, or a drug that acts on its receptor, and compared it against people who did not get it. Four studies that only WATCHED the body's own GLP-1 rise after a meal were removed, and those four were the only ones on this page that pointed in more than one direction: in them, GLP-1 and blood sugar rose together, which the authors themselves read as GLP-1 responding to the meal rather than blunting it. Each removal was correct on its own paper. Together they mean the unanimity you see is unanimity among drug trials, and this page does not yet settle what the hormone does at its natural levels.
📅 Last reviewed: 2026-07-15 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: Human trials (RCT / n-of-1)
MechanismIn-vitroAnimalObservationalRCTMeta-analysis
How the studies fall
12 support 0 contradict 0 tested null 0 mixed · 12 sources, 12 independent groups
What the evidence shows
GLP-1 stimulates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying and curbs appetite (the 'ileal brake') — the canonical physiology explaining why slowing nutrient delivery (lente carb, viscous fiber, RS) blunts glucose, and the backbone of the GLP-1-agonist drug class.
The evidence (25)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Becker RH, Stechl J, Steinstraesser A, Golor G, Pellissier F 2015 · Diabetes Metab Res Rev | RCT | supports | moderate | Randomised open-label crossover in 20 healthy adults: a single injection of lixisenatide (a GLP-1 receptor agonist) 60 minutes before a 600 kcal liquid meal cut the first-hour glucose area-under-the-curve by 61 to 121 mmol·min/L versus placebo, dose-dependently (all p<0.001), with no further gain above 10 µg. Doses of 5 µg or more slowed stomach emptying by more than half. Post-meal insulin fell rather than rose (first-hour insulin AUC 8,648 to 24,848 pmol·min/L lower), and the authors conclude the delayed stomach emptying, not an insulin effect, drove the glucose reduction. |
| Prasad S, Ahuja A, Sharma S, Nagda J, Agrawal S, Parmar V, Vardhan H 2026 · Cardiovasc Diabetol Endocrinol Rep | observational | mixed | low | Single case report: a 52-year-old non-obese man with type 2 diabetes lost glycemic control after 22 months stable on metformin plus sitagliptin - HbA1c rose from 6.7% to 8.4% over 8 months, with fasting glucose 168 mg/dL and 2-hour post-meal glucose 248 mg/dL - while beta-cell function stayed normal (fasting C-peptide 2.1 ng/mL, HOMA-beta 68%). Sitagliptin was stopped and bedtime insulin glargine started; HbA1c fell to 6.9% by 6 months. GLP-1 and GIP levels were never measured, so acquired incretin resistance remains the authors' hypothesis. |
| Juel CTB, Lund A, Andersen MM, Hansen CP, Storkholm JH, Rehfeld JF, van Hall G, Hartmann B, Wewer Albrechtsen NJ, Holst JJ, Vilsbøll T, Knop FK 2020 · Diabetologia | RCT | supports | high | In a double-blinded randomised crossover trial, 12 totally pancreatectomised patients and 12 healthy controls ate a liquid mixed meal after a single 20 microgram injection of the GLP-1 receptor agonist lixisenatide or placebo, with no insulin given on study days. In the pancreatectomised group lixisenatide cut the postprandial glucose rise from 1447 +/- 95 to 548 +/- 125 mmol/l x min (baseline-subtracted AUC, p < 0.001) and peak glucose from 23.3 to 18 mmol/l (p = 0.008); C-peptide was undetectable in these patients. It also slowed gastric emptying and cut postprandial glucagon. |
| Cui S, Kong H, Tian Y, Li D, Li C, Ban X, Gu Z, Li Z 2026 · Crit Rev Food Sci Nutr | mechanism | supports | moderate | A narrative review of how starch digestion rate and GLP-1 secretion interact. The authors report that slowly digestible and resistant starches appear to promote GLP-1 release by delivering their digestion by-products, glucose and short-chain fatty acids respectively, to L-cells in the distal gut, and that GLP-1 in turn delays gastric emptying and suppresses appetite via both the endocrine route and local paracrine activation of vagal afferents through GLP-1 receptors. It synthesises existing work rather than reporting new measurements, and calls the pathway not yet fully explored. |
| Chaikomin R, Doran S, Jones KL, Feinle-Bisset C, O'Donovan D, Rayner CK, Horowitz M 2005 · Am J Physiol Endocrinol Metab | RCT | mixed | moderate | Twelve healthy adults received 120 kcal of glucose straight into the small intestine on two days: once fast for the first 10 minutes (6 kcal/min) then slow (0.55 kcal/min), once steady at 1 kcal/min throughout. The fast start raised insulin, GIP and GLP-1 between 0 and 75 minutes, but blood glucose was higher over that period too; between 75 and 180 minutes both glucose and insulin were lower, and the overall 0-180 minute glucose area under the curve was the same on both days. Speeding glucose delivery to raise incretin hormones did not improve overall glycemia. |
| Kaur D, Chakrabarty S, Witzler C, Wang H, Wang M, Wolz R, Wilgenbus P, Posma JJN, Rachakonda S, Marini F, Zinina VV, Reyda S, Gogiraju R, Graf C, Samad F, Schäfer K, Reinhardt C, Soshnikova N, Ruf W, Madhusudhan T 2026 · JCI Insight | animal | supports | moderate | In obese mice, deleting the intestinal protease TMPRSS2 raised GLP-1 after an oral glucose load and lowered blood glucose, with GIP and insulin unchanged. Blocking the GLP-1 receptor with exendin(9-39) completely abolished that glucose improvement in males and largely abolished it in females; a ghrelin-receptor blocker removed both the GLP-1 rise and the glucose drop. A 3-week TMPRSS2 inhibitor reproduced it in db/db mice (n=6 per group). In lean mice a partial fall in GLP-1 left postprandial glucose unchanged. |
| Suganuma Y, Shimizu T, Sato T, Morii T, Fujita H, Harada Sassa M, Yamada Y 2020 · J Diabetes Investig | observational | supports | low | Eight Japanese adults with type 2 diabetes started a GLP-1 receptor agonist. Postprandial glucose fell at 120 and 180 minutes after one month (P=0.017 and P=0.043), and how far glucose rose in the first hour tracked how much the drug slowed gastric emptying (r2=0.78, P<0.001). The split matters: the four on short-acting drugs slowed emptying and blunted the first-hour rise (both P<0.02), while the four on long-acting liraglutide changed neither at one month. Open-label, single-arm, no control group, four patients per drug type. |
| Anjom-Shoae J, Veedfald S, Conigrave AD, Horowitz M, Feinle-Bisset C 2026 · Endocrine Reviews | observational | supports | moderate | A review of how calcium and the aromatic amino acids tryptophan and phenylalanine act on the gut's calcium-sensing receptor. In human studies these nutrients raised GLP-1 alongside CCK, GIP and PYY, cut intake at the next meal by roughly 90-500 kcal, and blunted the meal glucose rise - but the authors call the glucose effect modest: 3 g tryptophan lowered the glycemic response by about 1 mmol/L, and several calcium trials raised GLP-1 with no change in postprandial glucose. The review does not separate GLP-1's own contribution from the other hormones released. |
| Thazhath SS, Marathe CS, Wu T, Chang J, Khoo J, Kuo P, Checklin HL, Bound MJ, Rigda RS, Crouch B, Jones KL, Horowitz M, Rayner CK 2016 · Diabetes | RCT | supports | high | Double-blind randomized crossover trial in 10 healthy adults and 10 people with type 2 diabetes: intravenous exenatide (7.5 micrograms) or saline, with 45 g glucose infused into the duodenum over 60 minutes. With exenatide, duodenal pressure waves and antegrade flow events were fewer, intestinal transit was slower, and the areas under the curve for blood glucose and for the absorption marker 3-O-methylglucose were lower; insulin was initially lower, then higher. No numeric effect sizes are reported. Bypassing the stomach isolates a small-intestinal mechanism rather than testing a meal. |
| Nauck MA 1999 · Diabetologia | mechanism | supports | moderate | A 1999 physiology review asking whether GLP-1 is truly an incretin. It gathers the evidence that GLP-1, released from the lower intestine after eating, stimulates insulin secretion when blood glucose is high, suppresses glucagon, and slows gastric emptying and acid secretion — the 'ileal brake'. It notes that because exogenous GLP-1 slows the stomach so much in healthy people, the insulin response to a meal is reduced rather than augmented, so GLP-1's part in the normal incretin effect was not yet proven. It reviews published work rather than reporting experiments of its own. |
| Drucker DJ, Nauck MA 2006 · Lancet | mechanism | supports | high | A 2006 Lancet review of the incretin system. It sets out GLP-1 as a gut hormone that stimulates insulin, suppresses glucagon, inhibits gastric emptying and reduces appetite and food intake, and summarises trials of the GLP-1 drugs exenatide and liraglutide, which cut fasting and post-meal glucose and lowered HbA1c by 1-2% alongside 2-5 kg of weight loss; DPP-4 inhibitors lowered HbA1c by 0.5-1.0% without weight gain. It gathers published work rather than reporting experiments of its own, and says long-term trials are still needed. |
| Albaghlany RM, Mansour AA 2026 · Nutrition & Diabetes | observational | supports | moderate | Narrative review of incretin biology in type 2 diabetes. GLP-1 and GIP together account for about 50% of postprandial insulin secretion in people without diabetes, falling to 30% or less in type 2 diabetes, which the authors treat as a main cause of after-meal high blood sugar. The incretin contribution scales with the load: about 25% after 25 g of oral glucose versus 75-80% after 100 g. Alongside glucose-dependent insulin release, the review describes GLP-1 suppressing glucagon and slowing gastric emptying. The paper reports no measurements of its own; it summarises other studies. |
| Holst JJ 2007 · Physiol Rev | mechanism | supports | high | A physiology review of GLP-1, the hormone released from cells in the intestinal lining after a meal. It gathers the existing evidence that GLP-1's main actions are to stimulate insulin secretion and inhibit glucagon secretion, 'thereby contributing to limit postprandial glucose excursions', and that it also slows gut motility as part of the 'ileal brake'. The paper reviews and discusses work already published rather than reporting experiments of its own, so it adds no new measurement of how large the effect is. |
| De Block C, Benamar M, Fu A, Maltesen R, Giorgino F 2026 · eClinicalMedicine | RCT | supports | moderate | Post hoc analysis of blinded CGM data from the last 4 weeks of two 52-week randomised trials in type 2 diabetes. In COMBINE 1 (521 vs 541), adding the GLP-1 drug semaglutide to the same weekly basal insulin lowered the mean peak post-meal glucose rise by 4.2 mg/dL (61.6 vs 65.7), the 120-min rise by 12.2 mg/dL and the time to fall back below 140 mg/dL by 59.9 min (all p<0.0001); the 90-min glucose area did not differ (p=0.38). Against daily basal-bolus insulin (COMBINE 3, 301 vs 287) the peak rise was identical (p=0.97). Novo Nordisk funded; mealtimes were inferred by algorithm. |
| Zheng X, Xu Q, Wei Y, Chen F, Li G, Yu S, Ge J 2026 · Toxicol Appl Pharmacol | animal | supports | low | Drug-repurposing study in cells and mice, which the authors call preliminary. Bafetinib, a kinase inhibitor found by virtual screening, bound the GLP-1 receptor in binding assays and raised the receptor's cAMP-PKA-CREB signalling in cultured cells. Given orally to mice for 7 days it lowered postprandial blood glucose and body weight but not fasting glucose, reported as similar to the reference agonist exendin-4, with no organ toxicity seen. The paper reports no group sizes or effect sizes, and never tests whether the mouse glucose fall depends on the receptor. |
| Rayner CK, Watson LE, Phillips LK, Lange K, Bound MJ, Grivell J, Wu T, Jones KL, Horowitz M, Ferrannini E, Tricò D, Frascerra S, Mari A, Natali A 2020 · Diabetes Care | RCT | supports | high | In a double-blind randomized trial, 30 metformin-treated adults with type 2 diabetes took lixisenatide 20 ug daily or placebo for 8 weeks, then drank 75 g of glucose. After 8 weeks the stomach still emptied far more slowly on drug (240-min retention AUC ratio 2.19, 95% CI 1.82-2.64, P<0.001), with markedly lower incremental blood-glucose AUC (P<0.001) and slower appearance of the swallowed glucose in the blood (P<0.001). Glucose lowering tracked the degree of emptying slowing (r=-0.74, P=0.002), not beta-cell glucose sensitivity. ⚠️ correction-on-file (Crossref) - kept, corrigendum not retraction |
| Nauck MA, Muller TD 2023 · Diabetologia | mechanism | supports | moderate | A narrative review of incretin physiology in type 2 diabetes. It gathers published work showing that GLP-1 stimulates insulin secretion, suppresses glucagon, slows gastric emptying and reduces plasma glucose in both the fasting and postprandial states. Unlike GIP, whose insulinotropic action is largely lost in type 2 diabetes, GLP-1's is only mildly reduced - though its dose-response slope stays three to five times less steep than in healthy people. It reports no experiments of its own and gives no effect size for the glucose reduction. |
| Smits MM, Tonneijck L, Muskiet MH, Kramer MH, Cahen DL, van Raalte DH 2016 · Diabetes Obes Metab | mechanism | supports | high | A 2016 review of how GLP-1 lowers blood sugar through the gut rather than the pancreas. It gathers published work showing that GLP-1 'reduces gastric emptying rate and small bowel motility, thereby delaying glucose absorption and decreasing postprandial glucose excursions', and that short-acting GLP-1 drugs mainly cut post-meal glucose this way 'with little effect on insulin secretion', while long-acting ones mainly lower fasting glucose. A direct liver effect is described as suggested, not shown. The paper reports no experiments of its own and gives no effect sizes. |
| Kuwata H, Yabe D, Murotani K, Fujiwara Y, Haraguchi T, Kubota S, Kubota-Okamoto S, Usui R, Ishitobi M, Yamazaki Y, Hamamoto Y, Kurose T, Seino Y, Yamada Y, Seino Y 2021 · J Diabetes Investig | observational | supports | low | Eighteen Japanese adults with type 2 diabetes started one of three GLP-1 receptor agonists (lixisenatide 7, liraglutide 6, dulaglutide 5) and ate a standard 480 kcal meal before treatment and at 2 and 12 weeks. Glucose area under the curve over 240 minutes fell with all three drugs, and HbA1c fell from 8.58% to 6.45% by week 12. The route differed: lixisenatide slowed gastric emptying and suppressed glucagon and insulin; liraglutide raised insulin and barely slowed emptying; dulaglutide did neither. Single arm, no control group, 5-7 people per drug, no correction for multiple testing. |
| Benatar C, Zhang X, Haddam I, Ribes S, Bobet S, Monnoye M, Lamy E, Grassin-Delyle S, Juillard V, Layec S, Delorme C, Douard V 2026 · FASEB J | animal | supports | low | In male C57BL/6J mice, blocking the GLP-1 receptor with exendin (9-39) before an oral glucose test increased the glycaemic excursion versus untreated controls. The same blockade only partially attenuated the glucose-lowering effect of oral O-acetyl-serine (OAS) and left the early insulin rise unchanged, so the authors conclude GLP-1 receptor signalling is not the primary mediator of OAS's effect. OAS itself raised plasma GLP-1 (2.5-fold in prediabetic mice) but not GIP. The blockade rests on one experiment, a single 2 mg/kg antagonist dose, about six mice per group. |
| Krogh LSL, Hansen MB, Bergmann NC, Hansen CP, Hartmann B, Holst JJ, Knop FK, Lund AB, Gasbjerg LS 2026 · Diabetes Obes Metab | RCT | supports | moderate | Randomised, double-blind, placebo-controlled crossover in 12 adults with no pancreas: four 270-minute intravenous infusions each (GLP-1, GIP, both, saline) with a 480 kcal mixed meal. GLP-1 cut the post-meal glucose rise 45% +/- 48% versus saline (p=0.005) and slowed gastric emptying 29% +/- 36% on acetaminophen absorption (p=0.05). Insulin and C-peptide never differed between visits, so the glucose fall happened with no insulin secretion. GIP alone matched placebo. The authors call the study exploratory and note GLP-1 reached only about twice placebo levels, below the intended dose. |
| Heinonen S, Karppinen JE, Saarinen T, Groop PH, Juuti A, Holst JJ, Pietiläinen KH 2026 · Int J Obes (Lond) | observational | mixed | moderate | Randomized trial of two bypass operations in 41 adults with severe obesity (RYGB n=21, OAGB n=20), with 360-minute mixed-meal tests before and 6 and 12 months after surgery. Both raised total postprandial GLP-1 sharply (+330% RYGB, +259% OAGB) and both cut 12-month total glucose area under the curve (-9% and -11%). Early-phase glucose went the other way: 0-60 min glucose area rose 33% after RYGB and 12% after OAGB, peak glucose 39% and 9%. The arm with the bigger early GLP-1 rise (RYGB, +31%) also had the bigger early glucose rise (+19%) and higher peak (+28%). Secretin did not change. |
| Hoekx CA, Brinkman LBD, van Eenige R, Kooijman S, Muskiet MHA, Jazet IM, Martinez-Tellez B, Rensen PCN, Boon MR 2026 · Diabetes, Obesity and Metabolism | observational | mixed | low | Forty-nine young, lean Dutch adults - 24 of South Asian and 25 of European descent - gave blood seven times over four hours after a 300 kcal liquid meal; GLP-1 was measured, never given or blocked. Europids mostly showed a single glucose peak at 30 minutes and South Asians tended to peak again at 90, though the incremental glucose area did not differ by ethnicity in either sex. South Asian women had higher active GLP-1 and GIP late in the test while their glucose stayed high longer, which the authors say may be a consequence of that glucose rise. Post-meal fat levels matched. |
| Guo L, Sun Z, Zhang L, Qin G, Li Y, Chen X, Xu N, Su X, Mao L, Sun J, Cheng Z, Shi X, Wang F, Wang Q, Pan R, Ding S, Ye Z, Xu Y, Liu P 2026 · JAMA Network Open | RCT | supports | high | Phase 2, double-blind, placebo-controlled trial: 194 Chinese adults with type 2 diabetes on stable metformin took the oral GLP-1 receptor agonist HRS-7535 (15, 30, 60 or 90 mg daily) or placebo for 16 weeks. Two-hour post-meal glucose fell 99.6 to 152.3 mg/dL on drug versus 1.6 mg/dL on placebo - placebo-adjusted differences of 98 to 151 mg/dL, all P<0.001. HbA1c fell 0.94 to 1.57 percentage points more than placebo. Gastrointestinal side effects were common, and the trial was funded, run and statistically analysed by the manufacturer. |
| Tzeravini E, Simati S, Anastasiou IA, Dalamaga M, Kokkinos A 2026 · Curr Obes Rep | observational | supports | low | Narrative review of gut-hormone changes in type 2 diabetes and obesity. It states GLP-1's primary function is to enhance glucose-dependent insulin secretion while suppressing glucagon, thereby reducing hepatic glucose production, alongside slowed gastric emptying and reduced appetite. GLP-1 secretion itself is largely preserved in type 2 diabetes - recent meta-analyses found no consistent shortfall after an oral glucose load or mixed meal - while its insulin-stimulating and glucagon-suppressing actions are impaired. The review reports no measurements of its own. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.